The immune microenvironment and promising strategies for neuroblastoma therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Neuroblastoma is a malignant tumor found in children and characterized by exceptional heterogeneity and complex microenvironment which plays a key role in disease progression and response to therapy. The review summarizes the modern data on cell composition of neuroblastoma microenvironment and its effect on prognosis promoting formation of promising treatment strategies. Modulation of tumor microenvironment can become the key approach to development of effective targeted therapy and immunotherapy for various types of neuroblastoma.

About the authors

Gleb A. Karpov

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Author for correspondence.
Email: gleb13.karpov@gmail.com
ORCID iD: 0009-0001-3534-2911
Russian Federation, 1 Ostrovityanova St., Moscow 117513; 1 Samory Mashela St., Moscow 117198

A. E. Druy

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; Dr. Sergey Berezin Medical Institute

Email: gleb13.karpov@gmail.com
ORCID iD: 0000-0003-1308-8622
Russian Federation, 1 Samory Mashela St., Moscow 117198; lit. A, Bld. 3, 2 Esenina St., Saint Petersburg 194354

References

  1. Cheung N.V., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13(6):397–411. doi: 10.1038/nrc3526
  2. Blavier L., Yang R., DeClerck Y.A. The tumor microenvironment in neuroblastoma: new players, new mechanisms of interaction and new perspectives Cancers (Basel) 2020;12(10):2912. doi: 10.3390/cancers12102912
  3. Gunaydin G. CAFs interacting with TAMs in tumor microenvironment to enhance tumorigenesis and immune evasion. Front Oncol 2021;11:668349. doi: 10.3389/fonc.2021.668349
  4. Sahai E., Astsaturov I., Cukierman E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 2020;20(3):174–86. doi: 10.1038/s41568-019-0238-1
  5. Hashimoto O., Yoshida M., Koma Y. et al. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol 2016;240(2):211–23. doi: 10.1002/path.4769
  6. Mosser D.M., Edwards J P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8(12):958–69. doi: 10.1038/nri2448
  7. DeNardo D.G., Barreto J.B., Andreu P. et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16(2):91–102. doi: 10.1016/j.ccr.2009.06.018
  8. Ganesan A.P., Johansson M., Ruffell B. et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013;191(4):2009–17. doi: 10.4049/jimmunol.1301317
  9. Purwar R., Schlapbach C., Xiao S. et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18(8):1248–53. doi: 10.1038/nm.2856
  10. Sun Y., Xu S. Tumor-associated CD204-positive macrophage is a prognostic marker in clinical stage I lung adenocarcinoma. Biomed Res Int 2018;2018:8459193. doi: 10.1155/2018/8459193
  11. Asgharzadeh S., Salo J.A., Ji L. et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012;30(28):3525–32. doi: 10.1200/jco.2011.40.9169
  12. Zhang P., Wu X., Basu M. et al. MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database. Front Immunol 2017;8:1473. doi: 10.3389/fimmu.2017.01473
  13. Mina M., Boldrini R., Citti A. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. OncoImmunology 2015;4(9):e1019981. doi: 10.1080/2162402x.2015.1019981
  14. Zhong X., Zhang Y., Wang L. et al. Cellular components in tumor microenvironment of neuroblastoma and the prognostic value. Peer J 2019;7:e8017. doi: 10.7717/peerj.8017
  15. Morandi F., Pozzi S., Barco S. et al. CD4+CD25hiCD127− Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. OncoImmunology 2016;5(12):e1249553. doi: 10.1080/2162402x.2016.1249553
  16. Schaafsma E., Jiang C., Cheng C. B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. J Cancer Metastasis Treat 2021;7(34):10.20517/2394-4722.2021.72. doi: 10.20517/2394-4722.2021.72
  17. Mei S., Alchahin A.M., Embaie B.T. et al. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature. JCI Insight 2024;9(6):e173337. doi: 10.1172/jci.insight.173337
  18. Wei J.S., Kuznetsov I.B., Zhang S. et al. Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-cell receptors in HIGH-RISK MYCN-not-amplified human neuroblastoma. Clin Cancer Res 2018;24(22):5673–84. doi: 10.1158/1078-0432.ccr-18-0599
  19. Layer J.P., Kronmüller M.T., Quast T. et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. OncoImmunology 2017;6(6):e1320626. doi: 10.1080/2162402x.2017.1320626
  20. Raffaghello L., Prigione I., Airoldi I. et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004;6(5):558–68. doi: 10.1593/neo.04316
  21. Wienke J., Visser L.L., Kholosy W.M. et al. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer Cell 2024;42(2):283–300.e8. doi: 10.1016/j.ccell.2023.12.008
  22. Vanichapol T., Chutipongtanate S., Anurathapan U., Hongeng S. Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma. Biomed Res Int 2018;2018:1812535. doi: 10.1155/2018/1812535
  23. Castriconi R., Cantoni C., Della Chiesa M. et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003;100(7):4120–5. doi: 10.1073/pnas.0730640100
  24. Park Y.P., Choi S., Kiesler P. et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 2011;118(11):3019–27. doi: 10.1182/blood-2011-04-346825
  25. Gao Y., Souza-Fonseca-Guimaraes F., Bald T. et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 2017;18(9):1004–15. doi: 10.1038/ni.3800
  26. Zhen Z., Guo X., Liao R. et al. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion. Oncotarget 2016;7(28):44340–9. doi: 10.18632/oncotarget.10041
  27. Morandi F., Levreri I., Bocca P. et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007;67(13):6433–41. doi: 10.1158/0008-5472.can-06-4588
  28. Bergers G., Brekken R., McMahon G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2(10):737–44. doi: 10.1038/35036374
  29. Itatani Y., Yamamoto T., Zhong C. et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci USA 2020;117(35):21598–608. doi: 10.1073/pnas.2008112117
  30. Condamine T., Dominguez G.A., Youn J.I. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 2016;1(2):aaf8943. doi: 10.1126/sciimmunol.aaf8943
  31. Chao T., Furth E.E., Vonderheide R.H. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res 2016;4(11):968–82. doi: 10.1158/2326-6066.CIR-16-0188
  32. Morandi F., Barco S., Stigliani S. et al. Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget 2017;8(32):53194–209. doi: 10.18632/oncotarget.18285
  33. Zeng L., Liu X.-Y., Chen K. et al. Phosphoserine phosphatase as an indicator for survival through potentially influencing the infiltration levels of immune cells in neuroblastoma. Front Cell Dev Bio 2022;10:873710. doi: 10.3389/fcell.2022.873710
  34. Zhang Y., Zhang C., Ma Y. et al. Prediction to the prognosis of children with neuroblastoma by nomogram based on the first-diagnosed inflammatory markers. Pediatr Surg Int 2022;39(1):17. doi: 10.1007/s00383-022-05302-z
  35. Erbe A.K., Diccianni M.B., Mody R. et al. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group. J Immunother Cancer 2023;11(2):e006530. doi: 10.1136/jitc-2022-006530
  36. Fultang L., Gamble L.D., Gneo L. et al. Macrophage-derived IL1beta and TNFalpha regulate arginine metabolism in neuroblastoma. Cancer Res 2019;79(3):611–24. doi: 10.1158/0008-5472.CAN-18-2139
  37. Stip M.C., Teeuwen L., Dierselhuis M.P. et al. Targeting the myeloid microenvironment in neuroblastoma. J Exp Clin Cancer Res 2023;42(1):337. doi: 10.1186/s13046-023-02913-9
  38. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72(9):2162–71. doi: 10.1158/0008-5472.can-11-3687
  39. Matthay K.K., Blaes F., Hero B. et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Letters 2005;228(1–2):275–82. doi: 10.1016/j.canlet.2005.01.051
  40. Ding X., Yang W., Ren Q. et al. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma. J Neuroinflammation 2020;17(1):190. doi: 10.1186/s12974-020-01839-9
  41. Rudnick E., Khakoo Y., Antunes N.L. et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies – a report from the Children’s cancer group study. Med Pediatr Oncol 2001;36(6):612–22. doi: 10.1002/mpo.1138
  42. Gambini C., Conte M., Bernini G. et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virch Arch 2003;442(6):555–62. doi: 10.1007/s00428-002-0747-1
  43. Fukushima H., Inoue T., Takama Y. et al. Clinicopathological features of neuroblastic tumors with opsoclonus-myoclonus-ataxia syndrome: follicular structure predicts a better neurological outcome. Pathol Int 2017;67(10):503–9. doi: 10.1111/pin.12591
  44. Fühlhuber V., Bick S., Kirsten A. et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009;210(1–2):87–91. doi: 10.1016/j.jneuroim.2009.03.006
  45. Amini A., Lang B., Heaney D., Irani S.R. Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma. Neurology 2016;87(6):634–6. doi: 10.1212/wnl.0000000000002945
  46. Olgun N., Arayici M.E., Kızmazoglu D., Cecen R.E. Assessment of chemo-immunotherapy regimens in patients with refractory or relapsed neuroblastoma: a systematic review with meta-analysis of critical oncological outcomes. J Clin Med 2025;14(3):934. doi: 10.3390/jcm14030934
  47. Philippova J., Shevchenko J., Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol 2004;15:1371345. doi: 10.3389/fimmu.2024.1371345
  48. Theruvath J., Menard M., Smith B.A.H. et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med 2022;28(2):333–44. doi: 10.1038/s41591-021-01625-x
  49. Coronado E., Yañez Y., Vidal E. et al. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets. Mol Oncol 2021;15(2):364–80. doi: 10.1002/1878-0261.12868
  50. Liu X., Wills C.A., Chen L. et al. Tipifarnib inhibits the secretion of tumor-derived small extracellular vesicles and enhances the immunotherapeutic efficacy of dinutuximab in neuroblastoma. Cancer Res 2022;82(Suppl 12):4216. doi: 10.1158/1538-7445.am2022-4216
  51. Liu X., Wills C.A., Chen L. et al. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. J Immunother Cancer 2022;10(4):e004399. doi: 10.1136/jitc-2021-004399
  52. Rowshanrava B., Halliday N., Sansom D.M. CTLA-4: a moving target in immunotherapy. Blood 2017;131(1):58–67. doi: 10.1182/blood-2017-06-741033
  53. Mao C., Poimenidou M., Craig B.T. Current knowledge and perspectives of immunotherapies for neuroblastoma. Cancers 2024;16(16):2865. doi: 10.3390/cancers16162865
  54. Shirinbak S., Chan R.Y., Shahani S. et al. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. OncoImmunology 2021;10(1):1838140. doi: 10.1080/2162402x.2020.1838140
  55. Majzner R.G., Simon J.S., Grosso J.F. et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 2017;123(19):3807–15. doi: 10.1002/cncr.30724
  56. Alborzinia H., Chen Z., Yildiz U. et al. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med 2023;15(8):e18014. doi: 10.15252/emmm.202318014
  57. Nomura M., Ueno A., Saga K. et al. Accumulation of cytosolic calcium induces necroptotic cell death in human neuroblastoma. Cancer Res 2013;74(4):1056–66. doi: 10.1158/0008-5472.can-13-1283
  58. Galluzzi L., Kepp O., Hett E. et al. Immunogenic cell death in cancer: concept and therapeutic implications. J Transl Med 2023;21(1):162. doi: 10.1186/s12967-023-04017-6
  59. Mussai F., Egan S., Hunter S. et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Cancer Res 2015;75(15):3043–53. doi: 10.1158/0008-5472.can-14-3443
  60. Yau T., Cheng P.N., Chan P. et al. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs 2015;33(2):496–504. doi: 10.1007/s10637-014-0200-8
  61. Locatelli F., Pagliara D., De Ioris M.A. et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. Nat Med 2025;31(11):3689–99. doi: 10.1038/s41591-025-03874-6
  62. Li C., Sharma S., Heczey A.A. et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med 2025;31(4):1125–9. doi: 10.1038/s41591-025-03513-0
  63. Bosse K.R., Raman P., Zhu Z. et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell 2017;32(3):295–309:e12. doi: 10.1016/j.ccell.2017.08.003
  64. Li N., Fu H., Hewitt S.M. et al. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci USA 2017;114(32):E6623–31. doi: 10.1073/pnas.1706055114
  65. Moog-Lutz C., Degoutin J., Gouzi J.Y. et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280(28):26039–48. doi: 10.1074/jbc.m501972200
  66. Walker A.J., Majzner R.G., Zhang L. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther 2017;25(9):2189–201. doi: 10.1016/j.ymthe.2017.06.008
  67. Okada R., Reyes-González J.M., Rodriguez C. et al. GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL15/IL21 exhibit enhanced activity against neuroblastoma. Cancer Immunol Res 2025;13(9):1363–73. doi: 10.1158/2326-6066.cir-24-0975
  68. Giudice A.M., Roth S.L., Matlaga S. et al. Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells. Mol Ther 2025;33(9):4552–69. doi: 10.1016/j.ymthe.2025.05.025
  69. Zeromski J., Nyczak E., Dyszkiewicz W. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem Cytobiol 2001;39(Suppl. 2):36–7.
  70. Crossland D.L., Denning W.L., Ang S. et al. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene 2018;37(27):3686–97. doi: 10.1038/s41388-018-0187-2
  71. Bodden M., Häcker A., Röder J. et al. Co-expression of an IL-15 superagonist facilitates self-enrichment of GD2-targeted CAR-NK cells and mediates potent cell killing in the absence of IL-2. Cancers 2023;15(17):4310. doi: 10.3390/cancers15174310
  72. Moghimi B., Muthugounder S., Jambon S. et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun 2021;12(1):511. doi: 10.1038/s41467-020-20785-x
  73. Suurs F.V., Hooge M.N.L., De Vries E.G. et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther 2019;201:103–19. doi: 10.1016/j.pharmthera.2019.04.006
  74. Kitidee K., Amonyingcharoen S., Preedagasamzin S. et al. Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro. PLoS One 2025;20(6):e0325389. doi: 10.1371/journal.pone.0325389
  75. Muthukutty P., Yoo S.Y. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective. Viruses 2023;15(8):1645. doi: 10.3390/v15081645
  76. Chu Y., Tian M., Saini U. et al. Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma. Mol Ther Oncol 2024;33(1):200927. doi: 10.1016/j.omton.2024.200927
  77. Wing A., Fajardo C.A., Posey A.D. et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res 2018;6(5):605–16. doi: 10.1158/2326-6066.cir-17-0314
  78. Caescu C.I., Guo X., Tesfa L. et al. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21. Blood 2015;125(8):e1–13. doi: 10.1182/blood-2014-10-608000
  79. Mao Y., Eissler N., Blanc K.L. et al. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 2016;22(15):3849–59. doi: 10.1158/1078-0432.ccr-15-1912
  80. Wu H., Sheard M.A., Malvar J. et al. Anti-CD105 antibody eliminates tumor microenvironment cells and enhances anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells. Clin Cancer Res 2019;25(15):4761–74. doi: 10.1158/1078-0432.ccr-18-3358
  81. Rohila D., Park I.H., Pham T.V. et al. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma. Front Immunol 2023;14:1148317. doi: 10.3389/fimmu.2023.1148317

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

License URL: https://umo.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-57560 от  08.04.2014.